Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,473.84 56.31 0.39%
TOPIX 1,168.63 2.04 0.17%
HANG SENG 22,760.24 64.23 0.28%

InVivo Therapeutics’ Frank Reynolds Named a “CFO of the Year” Finalist by Boston Business Journal



  InVivo Therapeutics’ Frank Reynolds Named a “CFO of the Year” Finalist by
  Boston Business Journal

Business Wire

CAMBRIDGE, Mass. -- June 5, 2013

InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking
technologies for the treatment of spinal cord injuries (SCI) and other
neurotrauma conditions, today announced that InVivo’s Chief Executive Officer
and Chief Financial Officer Frank Reynolds has been named as a finalist in the
fifth annual Boston Business Journal’s CFO of the Year Awards. Reynolds has
been selected as a finalist in the Public Company category.

The Boston Business Journal’s annual CFO of the Year Awards luncheon
celebrates CFOs who have made a difference in their companies and
organizations. At the luncheon, which is scheduled for July 31, 2013,
finalists will be recognized and a winner for each of the five categories will
be announced. In addition to Public Company, the categories include Small
Private, Medium Private, Large Private and Non-Profit. The following CFOs are
nominated for Public Company CFO of the Year: Donald W. Palette of Skyworks
Solutions, Inc. (SWKS); Steven Lipiner of BNY Mellon Investment Management,
BNY Mellon (BK); and Christopher Menard of Brightcove Inc. (BCOV).

Said Reynolds, “My thanks to our Director of Finance, Sean Moran, and his
team, Albert Pasakarnis, Brian Luque, and Tatiana Monteiro, who are tasked
with executing on plan and under budget every day. Their efforts, along with
great legal representation from Greenberg Traurig, have allowed us to maximize
ROI around our cash investments in R&D. We’ve delivered a 10x return to
investors based on cash spend, and, as the largest shareholder of InVivo, I’m
certain we’ll continue our obsession with ROI-based spending while we prepare
to support revenue-generating products in 2014.”

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform
technology to develop treatments to improve function in individuals paralyzed
from traumatic spinal cord injuries. The company was founded in 2005 based on
proprietary technology co-invented by Robert S. Langer, ScD., Professor at
Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who is
affiliated with Massachusetts General Hospital. In 2011, the company earned
the prestigious David F. Apple Award from the American Spinal Injury
Association for its outstanding contribution to spinal cord injury medicine.
The publicly traded company is headquartered in Cambridge, MA. For more
details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Certain statements contained in this press release that are not historical
facts may constitute forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities and
Exchange Act of 1934, and the Company intends that such statements are subject
to the safe harbor created thereby. These statements include, but are not
limited to, those relating to the potential up-listing of our common stock to
a national securities exchange, and the impact of any such up-listing, such as
increasing liquidity and unlocking inherent value in our stock. These
forward-looking statements are based on current expectations, but are subject
to a number of risks and uncertainties. The factors that could cause actual
future results to differ materially from current expectations include, but are
not limited to, risks and uncertainties relating to the Company’s ability to
up-list to a national securities exchange, as well as other factors that are
identified and described in more detail in our Annual Report on Form 10-K for
the year ended December 31, 2012, and subsequent filings with the SEC.

Forward-looking statements contained in this press release speak only as of
the date of this release. Subsequent events or circumstances occurring after
such date may render these statements incomplete or out of date. The Company
undertakes no obligation and expressly disclaims any duty to update such
statements.

Contact:

InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
bluque@invivotherapeutics.com
Director, Investor Relations
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement